1093 N'un PE Oranı emsallerine kıyasla nasıldır?

1093 N, Price-To-Earnings değerine göre iyi bir değerdir. Eş ortalamaya (10.4x) kıyasla oran (26.1x).

1093 N'nin PE Oranı, Global Pharmaceuticals Sektöründeki diğer şirketlerle karşılaştırıldığında nasıldır?

1093 N Price-To-Earnings Oranı ( 10.4 x) baz alındığında, South American Pharmaceuticals sektör ortalamasına ( 8.6 x) kıyasla iyi bir değerdir.

1093 N'nin PE Oranı, Adil PE Oranına kıyasla nedir? Bu, şirketin tahmini kazanç büyümesini, kar marjlarını ve diğer risk faktörlerini dikkate alan beklenen PE Oranıdır.

Değerleme analizi için 1093 N 'in Price-To-Earnings Adil Oranını hesaplamak için yeterli veri yok.

Gelecekteki nakit akışlarına bakıldığında 1093 N 'un Adil Fiyatı nedir? Bu tahmin için İndirgenmiş Nakit Akışı modelini kullanıyoruz.

1093 N ( MX$15.69 ) [[adil değer]] tahminimizin altında işlem görüyor ( MX$25.64 )

Analistin 12 aylık tahmini nedir ve konsensüs fiyat hedefine istatistiksel olarak güveniyor muyuz?

Fiyat tahminini göstermek için yeterli veri yok.

CSPC Pharmaceutical Group (BMV:1093 N) - Hisse Senedi Fiyatı, Haberler ve Analizler

1093 N Stoklara Genel Bakış

An investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People’s Republic of China, other Asian regions, North America, Europe, and internationally. Daha fazla detay

1093 N temel anali̇z
Kar Tanesi Skoru
Değerleme	4/6
Gelecekteki Büyüme	0/6
Geçmiş Performans	3/6
Finansal Sağlık	6/6
Temettüler	3/6

Ödüller

Adil değer tahminimizden 38.8% daha düşük bir oranda işlem görüyor

Kazançlar son 5 yılda yılda 14.6% oranında arttı

Risk Analizi

Hisse senetleri oldukça likit değildir

4.75% temettüsü serbest nakit akışları tarafından iyi karşılanmıyor

CSPC Pharmaceutical Group Limited Rakipler

Genomma Lab Internacional. de

BMV:LAB B

Mex$24.7b

Aurobindo Pharma

NSEI:AUROPHARMA

₹708.6b

Ipsen

ENXTPA:IPN

€8.8b

Kyowa Kirin

TSE:4151

JP¥1.3t

Fiyat Geçmişi ve Performans

için tüm zamanların en yüksek seviyelerinin, değişikliklerin ve fiyat düşüşlerinin özeti CSPC Pharmaceutical Group
Tarihsel hisse senedi fiyatları
Güncel Hisse Fiyatı	HK$15.69
52 Haftanın En Yüksek Seviyesi	HK$15.69
52 Haftanın En Düşük Seviyesi	HK$15.69
Beta	0.71
11 Aylık Değişim	0%
3 Aylık Değişim	n/a
1 Yıllık Değişim	-27.02%
33 Yıllık Değişim	n/a
5 Yıllık Değişim	n/a
Halka arzdan bu yana değişim	-41.10%

Son Haberler & Güncellemeler

Recent updates

Hissedar Getirileri

	1093 N	MX Pharmaceuticals	MX Pazar
7D	0%	-2.2%	-0.9%
1Y	-27.0%	-20.7%	-4.7%

Getiri vs. Endüstri: 1093 N geçen yıl boyunca % -20.7 oranında getiri sağlayan MX Pharmaceuticals sektörüyle eşleşti.

Getiri vs Piyasa: 1093 N geçen yıl % -4.7 oranında getiri sağlayan MX Piyasasının altında performans gösterdi.

Fiyat Oynaklığı

Is 1093 N's price volatile compared to industry and market?
1093 N volatility
1093 N Average Weekly Movement	n/a
Pharmaceuticals Industry Average Movement	6.6%
Market Average Movement	4.0%
10% most volatile stocks in MX Market	6.1%
10% least volatile stocks in MX Market	2.6%

İstikrarlı Hisse Senedi Fiyatı: 1093 N son 3 ayda önemli bir fiyat oynaklığı yaşamadı.

Zaman İçindeki Volatilite: 1093 N 'un son bir yıldaki oynaklık değişimini belirlemek için Yetersiz veri.

Şirket Hakkında

Kuruldu	Çalışanlar	CEO	Web sitesi
1992	25,587	Cuilong Zhang	www.cspc.com.hk

CSPC Pharmaceutical Group Limited Temel Bilgiler Özeti

CSPC Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır?
1093 N temel i̇stati̇sti̇kler
Piyasa değeri	Mex$151.69b
Kazançlar(TTM)	Mex$14.61b
Gelir(TTM)	Mex$74.74b

10.4x

F/K Oranı

2.0x

P/S Oranı

1093 N aşırı değerli mi?

Gerçeğe Uygun Değer ve değerleme analizine bakınız

Kazanç ve Gelir

En son kazanç raporundan temel karlılık istatistikleri (TTM)
1093 N gelir tablosu (TTM)
Gelir	CN¥31.31b
Gelir Maliyeti	CN¥9.34b
Brüt Kâr	CN¥21.97b
Diğer Giderler	CN¥15.85b
Kazançlar	CN¥6.12b

Son Raporlanan Kazançlar

Sep 30, 2023

Sonraki Kazanç Tarihi

n/a

Hisse başına kazanç (EPS)	0.52
Brüt Marj	70.17%
Net Kâr Marjı	19.54%
Borç/Özkaynak Oranı	1.2%

1093 N uzun vadede nasıl bir performans gösterdi?

Geçmiş performansı ve karşılaştırmayı görün

Temettüler

4.7%

Mevcut Temettü Verimi

44%

Ödeme Oranı

1093 N Stoklara Genel Bakış

Ödüller

Risk Analizi

CSPC Pharmaceutical Group Limited Rakipler

BMV:LAB B

Mex$24.7b

NSEI:AUROPHARMA

₹708.6b

ENXTPA:IPN

€8.8b

TSE:4151

JP¥1.3t

Fiyat Geçmişi ve Performans

Son Haberler & Güncellemeler

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

Recent updates

CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024

CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA

CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares.

CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024

CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024

CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval

CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023

CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024

CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023

CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S

CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval

CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024

CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024

CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024

CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration

CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA

CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets

CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023

CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China

New major risk - Earnings quality

Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE

CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors

CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA

CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023

CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023

Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161)

CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China

CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301

Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China

Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023

CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022

CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023

Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021)

CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval

Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval

CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S

Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China

CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S

Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021)

CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration

CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule

CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022

CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director

CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002

CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis